Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by ...

The funds will be used to advance Agomab’s candidates through clinical trials, including AGMB-129 for patients with ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, drug pipeline outlook, the ...

Sanofi reported stronger-than-expected third-quarter earnings on Friday, driven by early vaccine sales and robust performance ...

Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales.

Holcim's spin-off of its North American business is progressing "extremely well", Chief Financial Officer Steffen Kindler ...

Agomab Therapeutics NV (‘Agomab’) today announced a $89 million (€82.1 million) Series D financing round, with participation ...

- Subdued session overall but looking forward to an action-pack week ahead. Session saw cautious tone as market's focus on ...

Europe starts cautiously after mixed closing in US and Asia. In Milan eyes on Eni after the quarterly, banks on the rise ...

NUPCO signs over 15 new MoUs at the Global Health Exhibition 2024, deepening its ties with the private sector and advancing ...

Global stocks were trading higher on Friday, although they were set for a weekly loss amid US election jitters, while oil ...